ADA/EASD Issue New Management Guidelines (see this week’s Item #2) and FDA Rejects Diabetes Drug Alogliptin (see this week’s Item #10).
ADA/EASD Issue New Management Guidelines (see this week’s Item #2) and FDA Rejects Diabetes Drug Alogliptin (see this week’s Item #10).
|
|
|
|